Compare Iris Energy Limited (IREN) vs Natera Inc. Common Stock (NTRA) Price & Performance

IREN trades at $34.80, showing no change in the last 24 hours. The stock faces bearish technical signals with recent earnings misses and a significant net loss margin of -99.38% in 2026 projections. Despite this, analyst consensus remains strongly bullish with an $81.00 price target, citing the company's pivot to AI infrastructure and major contracts with Microsoft and NVIDIA. Recent news highlights investor concerns over the $30 billion spending plan and execution risks amid the broader AI infrastructure boom.

The outlook for IREN hinges on successful execution of its AI pivot and capital-intensive expansion. While Wall Street sees substantial upside potential, risks include ballooning losses, high valuation multiples, and intense competition in the neocloud space. Investors should weigh the long-term growth narrative against near-term financial pressures and market volatility.

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.